# TAK-242 in Patients With Acute Alcoholic Hepatitis

> **NCT04620148** · PHASE2 · UNKNOWN · sponsor: **Akaza Bioscience Ltd** · enrollment: 100 (estimated)

## Conditions studied

- Acute-On-Chronic Liver Failure

## Interventions

- **DRUG:** TAK-242
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04620148
- **Lead sponsor:** Akaza Bioscience Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04620148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04620148, "TAK-242 in Patients With Acute Alcoholic Hepatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04620148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*